About ABK Biomedical Inc.
ABK Biomedical is a clinical-stage medical device company focused on developing innovative therapies for liver tumors, including their investigational Eye90 microspheres for Yttrium-90 radioembolization.
Company Background
Founded in 2012, ABK Biomedical is dedicated to researching, developing, and commercializing breakthrough medical device therapies aimed at improving outcomes for patients with benign and malignant hypervascular tumors abkbiomedical.com+1. The company combines expertise in engineering, material science, oncology, medical science, regulatory affairs, and clinical study coordination to advance personalized healthcare in oncology abkbiomedical.com
Key Technology: Eye90 Microspheres
ABK Biomedical’s flagship product, Eye90 microspheres®, is an investigational therapy designed for Yttrium-90 (Y-90) radioembolization, a targeted treatment for liver cancer abkbiomedical.com+1. These microspheres are made from a proprietary, imageable glass composition, allowing direct visualization during procedures to improve precision and treatment efficacy abkbiomedical.com+1. Eye90 is currently under evaluation in the Route90 pivotal FDA IDE clinical trial for hepatocellular carcinoma (HCC) and is not yet FDA-approved for general use abkbiomedical.com+1.
Partnerships and Collaborations
ABK Biomedical has established strategic partnerships to support development and commercialization. Notably, the company has a long-term agreement with the University of Missouri Research Reactor (MURR), which serves as the primary irradiation partner for Eye90 microspheres, ensuring scalable and reliable production of the therapy missouri.edu. This collaboration builds on seven years of prior work and supports global access to novel cancer treatments.
Funding and Growth
In October 2025, ABK Biomedical raised US$35 million in Series D financing, led by J.P. Morgan Life Sciences Private Capital, to support ongoing clinical operations, commercialization preparation, and expansion of manufacturing and supply chain capabilities PR Newswire. The company also holds intellectual property in inorganic polymer microspheres and unique administration systems, reinforcing its position in embolotherapy innovation PR Newswire.
Mission and Vision
ABK Biomedical emphasizes advancing medical innovation and improving patient outcomes. The company fosters a stimulating work environment and collaborates with organizations and individuals with exceptional scientific expertise and ethical standards abkbiomedical.com+1. Their focus is on transforming liver cancer treatment through cutting-edge device technologies and personalized oncology solutions.
Additional Activities
Beyond clinical development, ABK Biomedical actively participates in industry events, such as the GEST Annual Meeting, showcasing Eye90 microspheres and other resorbable microsphere technologies LinkedIn. The company also engages in community and team-building activities, reflecting a dynamic corporate culture LinkedIn.
